Abstract 1082
Background
Older cancer patients are a vulnerable group of medication users. Pharmacist-led medication reviews may optimize treatment and thereby reduce the risk of harmful effects from medication use. This study aims to determine the prevalence and management of Potentially Inappropriate Medication use (PIM’s) and Potential Omissions in Medication (POM’s) in older cancer patients.
Methods
In this prospective observational study (hospital) pharmacists conducted medication reviews with older cancer patients (aged ≥65 years) treated with parenteral chemo and/or immunotherapy to determine the prevalence of PIM’s and POM’s. PIM’s and POM’s were identified using the Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP), the screening Tool to Alert doctors to the Right Treatment (START) and pharmacists’ expert opinion. Recommendations regarding PIM’s and POM’s were made to the patient’s oncologist/haematologist and follow-up was measured. Associations between covariates and the prevalence of PIM’s and POM’s were statistically analysed.
Results
117 (78%) of the 150 patients included (median age 72 years, 59% male, 68% solid tumours, mean number of medicines 11) had at least one PIM and/or PIM. In total 266 PIM’s and POM’s were identified, and these led to 195 (73%) follow-up actions (table). The number of medicines and Charlson Comorbidity Index score (as a measure of vulnerability) were both independently associated with having at least one PIM and/or POM (p = .031 and p = .002 respectively).Table:
1825P Identification and follow-up of PIM’s and POM’s
PIM’s and POM’s | |
---|---|
n (%) | |
PIM’s, total Using STOPP | 180 89 (49) |
Using expert opinion | 85 (47) |
Using both | 6 (3) |
POM’s, total Using START | 86 66 (77) |
Using expert opinion | 20 (23) |
Follow-up actions By oncologist/haematologist | 266 77 (29) |
By general practitioner | 118 (44) |
No follow-up action | 71 (27) |
Conclusions
PIM’s and POM’s are highly prevalent among older cancer patients. A pharmacist-led medication review using STOPP/START criteria and pharmacists’ expert opinion is an excellent way to identify these PIM’s and POM’s and to optimize patients’ medication use. The majority of recommendations made regarding PIM’s and POM’s leads to a follow-up action.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Deventer Teaching Hospital.
Funding
Has not received any funding.
Disclosure
F.G.A. Jansman: Advisory / Consultancy, 2016: Amgen; Advisory / Consultancy, 2016: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract